Anti-Viral Therapies Market Key Players Analysis 2031
The global anti-viral therapies market is expected to grow from US$ 47,228.91 million in 2021 to US$ 82,928.76 million in 2031; it is estimated to grow at a CAGR of 8.4% from 2022 to 2031.
Anti-viral therapies involve the development of a treatment for viral infections. There are several strategies used to develop anti-viral therapy, including direct-acting anti-virals that target viral proteins, enzymes, or nucleic acids; passive antibodies that neutralize circulating viruses; and drugs that target cellular proteins or processes essential for viral replication.
The anti-viral therapies market is attributed to the increasing R&D expenditures in pharmaceutical companies and rising government support for research activities and clinical trials. However, the high cost of drug development is hampering the growth of the market.
The anti-viral therapies market is segmented on the basis of type, application, mechanism of action, and geography. The report offers insights and in-depth analysis of the anti-viral therapies market, emphasizing various parameters such as market trends, technological advancements, and market dynamics, as well as the competitive landscape analysis of leading market players.
Market Insights
Increasing R&D Expenditures in Pharmaceutical Companies Bolsters Anti-Viral Therapies Market Growth
Research and development (R&D) is an essential part of a company’s business. Pharmaceutical companies focus on R&D to introduce new drugs with enhanced medical and commercial potential. These companies invest majorly in R&D activities with an aim to deliver high-quality and innovative products in the market.
R&D Investments by Major Pharmaceutical Companies
Note: Current conversion rate is considered.
Source: Annual Reports and The Insight Partners Analysis
R&D spending by the biopharmaceutical companies has increased over the years. According to the report of the Pharmaceutical Research and Manufacturers of America (PhRMA), the R&D expenditure of biopharmaceutical companies increased from US$ 49.6 billion in 2012 to US$ 58.8 billion in 2015. In the fiscal year 2014–2015, 16 pharmaceutical companies were among the world’s top 50 companies in terms of total R&D investment. Novartis, Roche, Johnson & Johnson, and Pfizer are among the top 10 leading R&D investing companies globally. Further, in 2021, Astellas Pharma invested US$ 1803.70 million in the R&D of new and advanced drugs. Thus, an increase in R&D expenditure is anticipated to drive the anti-viral therapies market during the forecast period.
Type-Based Insights
Based on type, the anti-viral therapies market is bifurcated into generic drugs and branded drugs. The branded drugs segment held a larger share of the market in 2021; however, the generic drugs segment is anticipated to register a higher CAGR during the forecast period.
Mechanism of Action-Based Insights
Based on mechanism of action, the anti-viral therapies market is segmented into nucleotide polymerase inhibitor, reverse transcriptase inhibitors, protease inhibitors, and others. The nucleotide polymerase inhibitor segment held the largest share of the market in 2021; also, the reverse transcriptase inhibitors segment is anticipated to register the highest CAGR in the market during the forecast period due to its effectiveness in reducing the spread of viral infections. Hence, the need and use of reverse transcriptase inhibitors are expected to increase in the coming years, which is likely to fuel the market growth across the globe.
Application-Based Insights
Based on application, the global anti-viral therapies market is segmented into HIV, hepatitis, herpes, virus influenza, and other applications. The HIV segment held the largest share of the market in 2021. Further, the hepatitis segment is estimated to register the highest CAGR during the forecast period.
By geography, the global market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).
The Asia Pacific anti-viral therapies market is expected to grow at the fastest rate during the forecast period. The market is estimated to grow during the forecast period due to the rising pharmaceutical industry in China, Japan, India, and other Asia Pacific countries. The increasing incidences of viral diseases in the region and growing product developments by the local as well as international market players is likely to favor market growth. Further, China's pharmaceutical industry is among the largest pharmaceutical industry across the globe. The country has shown significant growth in active pharmaceutical ingredient manufacturing, competitiveness, innovations, and final dosage formation. Hence, most multinational companies are showing interest in the Chinese market for drug sales.
Growing efforts by governments of various countries and pharmaceutical and biotech companies to treat COVID-19 patients are likely to propel the growth of the anti-viral therapies market during the forecast period. In the US, the FDA has approved the emergency-use authorization of experimental drugs. Clinical trials of remdesivir, monoclonal antibodies, interferons, ACE inhibitors, and hydroxychloroquine have all been registered in the US. Furthermore, pharmaceutical companies in the country are making tremendous efforts to develop drugs and vaccines for the treatment of COVID-19 patients. In June 2021, scientists from the University of Oxford had been testing existing drugs as therapies for COVID-19 patients. Furthermore, The European Commission in July authorized remdesivir, making it the first approved drug for the treatment of COVID-19 in the European Union.
Company Profiles
A few of the major players operating in the anti-viral therapies market include AbbVie Inc.; Abbott; F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Gilead Sciences, Inc.; GlaxoSmithKline plc; and Aurobindo Pharma Limited.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, Mechanism of Action, and Application
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
The anti-viral therapies market majorly consists of the players such as AbbVie Inc., Abbott, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Merck & Co., Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, AstraZeneca and Aurobindo Pharma Limited amongst others.
The factors that are driving growth of the market are growing prevalence of viral diseases, increasing R&D expenditures in pharmaceutical companies and rising government support for research activities and clinical trials. Moreover, emerging markets is expected to offer lucrative opportunities for the growth of the market.
Antiviral therapies is one of the most exciting branches of virology, which involves developing a treatment for viral infections. There are several strategies used to develop antiviral therapy, including direct-acting antivirals that target viral proteins, enzymes, or nucleic acids; passive antibodies that neutralize circulating viruses; drugs that target cellular proteins or processes essential for viral replication.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Anti - Viral Therapies Market – By Type
1.3.2 Global Anti - Viral Therapies Market – By Mechanism of Action
1.3.3 Global Anti-viral therapies market – By Application
1.3.4 Global Anti - Viral Therapies Market – By Geography
2. Anti-Viral Therapies Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Global Anti-Viral Therapies – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America – PEST Analysis
4.2.2 Europe – PEST Analysis
4.2.3 Asia Pacific – PEST Analysis
4.2.4 Middle East and Africa (MEA) – PEST Analysis
4.2.5 South and Central America (SCAM) – PEST Analysis
4.3 Expert Opinions
5. Anti-Viral Therapies Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing R&D Expenditures in Pharmaceutical Companies
5.1.2 Rising Government Support for Research Activities and Clinical Trials
5.2 Market Restraints
5.2.1 High Cost of Drug Development
5.3 Market Opportunities
5.3.1 Emerging Markets
5.4 Future Trends
5.4.1 Growing Emphasis on Launching Anti-Viral Agents
5.5 Impact analysis
6. Anti-Viral Therapies Market – Global Analysis
6.1 Global Anti-Viral Therapies Market Revenue Forecast And Analysis
6.2 Global Anti- Viral Therapies Market, By Geography - Forecast And Analysis
6.3 Market Positioning of Key Players
7. Anti - Viral Therapies Market Analysis – By Type
7.1 Overview
7.2 Anti-viral therapies market Revenue Share, by Type (2019 and 2027)
7.3 Generic Drugs
7.3.1 Overview
7.3.2 Generic Drugs: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)
7.4 Branded Drugs
7.4.1 Overview
7.4.2 Branded Drugs: Anti-viral therapies market – Revenue and Forecast to 2027 (US$ Million)
8. Anti-Viral Therapies Market Analysis – By Mechanism of Action
8.1 Overview
8.2 Anti-Viral Therapies Market Revenue Share, by Mechanism Of Action (2019 and 2027)
8.3 Nucleotide Polymerase Inhibitor
8.3.1 Overview
8.3.2 Nucleotide Polymerase Inhibitor: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Reverse Transcriptase Inhibitors
8.4.1 Overview
8.4.2 Reverse Transcriptase Inhibitors: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)
8.5 Protease Inhibitors
8.5.1 Overview
8.5.2 Protease Inhibitors: Anti-viral therapies market – Revenue and Forecast to 2027 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Anti-viral therapies market – Revenue and Forecast to 2027 (US$ Million)
9. Anti-Viral Therapies Market Analysis – By Application
9.1 Overview
9.2 Anti-Viral Therapies Market Share, by Application, 2019 and 2027, (%)
9.3 HIV
9.3.1 Overview
9.3.2 HIV: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)
9.4 Hepatitis
9.4.1 Overview
9.4.2 Hepatitis: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)
9.5 Herpes
9.5.1 Overview
9.5.2 Herpes: Anti-viral therapies market – Revenue and Forecast to 2027 (US$ Million)
9.6 Influenza
9.6.1 Overview
9.6.2 Influenza: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)
9.7 Other Applications
9.7.1 Overview
9.7.2 Other Applications: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)
10. Anti-Viral Therapies Market – Geographic Analysis
10.1 North America: Anti-Viral Therapies Market
10.1.1 Overview
10.1.2 North America: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.1.3 North America: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.1.4 North America: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.1.5 North America: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.1.6 North America: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)
10.1.7 US: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.1.7.1 US: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.1.7.2 US: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.1.7.3 US: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.1.7.4 US: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.1.8 Canada: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.1.8.1 Canada: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.1.8.2 Canada: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.1.8.3 Canada: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.1.8.4 Canada: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.1.9 Mexico: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.1.9.1 Mexico: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.1.9.2 Mexico: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.1.9.3 Mexico: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.1.9.4 Mexico: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.2 Europe: Anti-Viral Therapies Market
10.2.1 Overview
10.2.2 Europe: Anti-Viral Therapies Market - Revenue and Forecast to 2027 (USD Million)
10.2.3 Europe: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.2.4 Europe: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.2.5 Europe: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.2.6 Europe: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)
10.2.7 Germany: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.2.7.1 Germany: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.2.7.2 Germany: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.2.7.3 Germany: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.2.7.4 Germany: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.2.8 UK: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.2.8.1 UK: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.2.8.2 UK: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.2.8.3 UK: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.2.8.4 UK: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.2.9 France: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.2.9.1 France: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.2.9.2 France: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.2.9.3 France: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.2.9.4 France: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.2.10 Spain: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.2.10.1 Spain: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.2.10.2 Spain: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.2.10.3 Spain: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.2.10.4 Spain: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.2.11 Italy: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.2.11.1 Italy: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.2.11.2 Italy: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.2.11.3 Italy: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.2.11.4 Italy: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.3 Asia Pacific: Anti-Viral Therapies Market
10.3.1 Overview
10.3.2 Asia Pacific: Anti-Viral Therapies Market - Revenue and Forecast to 2027 (USD Million)
10.3.3 Asia Pacific: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.3.4 Asia Pacific: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.3.5 Asia Pacific: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.3.6 Asia Pacific: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)
10.3.7 China: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.3.7.1 China: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.3.7.2 China: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.3.7.3 China: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.3.7.4 China: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.3.8 Japan: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.3.8.1 Japan: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.3.8.2 Japan: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.3.8.3 Japan: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.3.8.4 Japan: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.3.9 India: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.3.9.1 India: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.3.9.2 India: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.3.9.3 India: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.3.9.4 India: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.3.10 South Korea: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.3.10.1 South Korea: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.3.10.2 South Korea: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.3.10.3 South Korea: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.3.10.4 South Korea: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.3.11 Australia: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.3.11.1 Australia: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.3.11.2 Australia: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.3.11.3 Australia: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.3.11.4 Australia: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.4 Middle East & Africa: Anti-Viral Therapies Market
10.4.1 Overview
10.4.2 Middle East & Africa: Anti-Viral Therapies Market - Revenue and Forecast to 2027 (US$ Million)
10.4.3 Middle East & Africa: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.4.4 Middle East & Africa Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)
10.4.5 Middle East & Africa Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
10.4.6 Middle East & Africa: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)
10.4.7 Saudi Arabia: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.4.7.1 Saudi Arabia: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.4.7.2 Saudi Arabia: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.4.7.3 Saudi Arabia Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)
10.4.7.4 Saudi Arabia Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
10.4.8 UAE: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.4.8.1 UAE: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.4.8.2 UAE: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.4.8.3 UAE Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)
10.4.8.4 UAE Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
10.4.9 South Africa: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.4.9.1 South Africa: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.4.9.2 South Africa: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.4.9.3 South Africa Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)
10.4.9.4 South Africa Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
10.5 South and Central America: Anti-Viral Therapies Market
10.5.1 Overview
10.5.2 South and Central America: Anti-Viral Therapies Market - Revenue and Forecast to 2027 (US$ Million)
10.5.3 South and Central America: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.5.4 South and Central America: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.5.5 South and Central America: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.5.6 South and Central America: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)
10.5.7 Brazil: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.5.7.1 Brazil: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.5.7.2 Brazil: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.5.7.3 Brazil: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.5.7.4 Brazil: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
10.5.8 Argentina: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.5.8.1 Argentina: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
10.5.8.2 Argentina: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)
10.5.8.3 Argentina: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)
10.5.8.4 Argentina: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)
11. Impact of COVID-19 Pandemic on Global Anti-Viral Therapies Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
11.2 Europe: Impact Assessment of COVID-19 Pandemic
11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
11.4 Rest of World: Impact Assessment of COVID-19 Pandemic
12. Anti-Viral Therapies Market – Industry Landscape
12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market, (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 Abbott
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 AbbVie Inc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Bristol-Myers Squibb Company
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Johnson and Johnson Services, Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Merck & Co., Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Gilead Sciences, Inc.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 GlaxoSmithKline plc.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 AstraZeneca
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Aurobindo Pharma Ltd
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 F. HOFFMANN-LA ROCHE LTD.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. R&D Investments by Major Pharmaceutical Companies
Table 2. North America Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 3. North America Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)
Table 4. North America Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 5. US Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 6. US Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)
Table 7. US Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 8. Canada Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 9. Canada Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)
Table 10. Canada Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 11. Mexico Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 12. Mexico Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)
Table 13. Mexico Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 14. Europe Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 15. Europe Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)
Table 16. Europe Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 17. Germany Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 18. Germany Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)
Table 19. Germany Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 20. UK Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 21. UK Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)
Table 22. UK Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 23. France Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 24. France Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)
Table 25. France Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 26. Spain Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 27. Spain Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)
Table 28. Spain Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 29. Italy Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 30. Italy Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)
Table 31. Italy Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 32. Asia Pacific Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 33. Asia Pacific Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)
Table 34. Asia Pacific Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 35. China Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 36. China Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)
Table 37. China Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 38. Japan Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 39. Japan Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)
Table 40. Japan Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 41. India Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 42. India Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)
Table 43. India Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 44. South Korea Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 45. South Korea Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)
Table 46. South Korea Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 47. Australia Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 48. Australia Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)
Table 49. Australia Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 50. Middle East & Africa Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 51. Middle East & Africa Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)
Table 52. Middle East & Africa Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 53. Saudi Arabia Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 54. Saudi Arabia Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)
Table 55. Saudi Arabia Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 56. UAE Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 57. UAE Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)
Table 58. UAE Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 59. South Africa Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 60. South Africa Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)
Table 61. South Africa Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 62. South and Central America Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 63. South and Central America Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)
Table 64. South and Central America Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 65. Brazil Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 66. Brazil Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)
Table 67. Brazil Anti-Viral Therapies Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 68. Argentina Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 69. Argentina Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027 (USD Million)
Table 70. Argentina Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 71. Organic Developments Done By Companies
Table 72. Inorganic Developments Done by Companies
Table 73. Glossary of Terms, Anti-Viral Therapies Market
LIST OF FIGURES
Figure 1. Anti-Viral Therapies Market Segmentation
Figure 2. Anti-Viral Therapies Market Segmentation, By Region
Figure 3. Anti-Viral Therapies Market Overview
Figure 4. Branded Drugs Segment Held Largest Share of Anti-Viral Therapies Market
Figure 5. APAC to Show Significant Growth During Forecast Period
Figure 6. Anti- Viral Therapies Market, by Geography (US$ Million)
Figure 7. Global Anti -Viral Therapies Market – Leading Country Markets (US$ Million)
Figure 8. Global Anti-Viral Therapies Market, Industry Landscape
Figure 9. North America PEST Analysis
Figure 10. Europe PEST Analysis
Figure 11. Asia Pacific PEST Analysis
Figure 12. Middle East and Africa (MEA) PEST Analysis
Figure 13. South and Central America (SCAM) PEST Analysis
Figure 14. Anti-Viral Therapies Market Impact Analysis of Driver and Restraints
Figure 15. Global Anti-Viral Therapies Market – Revenue Forecast And Analysis – 2019- 2027
Figure 16. Global Anti- Viral Therapies Market – By Geography Forecast and Analysis – 2019- 2027
Figure 17. Market Positioning Of Key Players In Global Anti- Viral Therapies Market
Figure 18. Anti-viral therapies market Revenue Share, by Type (2019 and 2027)
Figure 19. Generic Drugs: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)
Figure 20. Branded Drugs: Anti-viral therapies market – Revenue and Forecast to 2027 (US$ Million)
Figure 21. Anti-Viral Therapies Market Revenue Share, by Mechanism Of Action (2019 and 2027)
Figure 22. Nucleotide Polymerase Inhibitor: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)
Figure 23. Reverse Transcriptase Inhibitors: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)
Figure 24. Protease Inhibitors: Anti-viral therapies market – Revenue and Forecast to 2027 (US$ Million)
Figure 25. Others: Anti-viral therapies market – Revenue and Forecast to 2027 (US$ Million)
Figure 26. Anti-Viral Therapies Market Share, by Application, 2019 and 2027 (%)
Figure 27. HIV: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)
Figure 28. Hepatitis: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)
Figure 29. Herpes: Anti-viral therapies market – Revenue and Forecast to 2027 (US$ Million)
Figure 30. Influenza: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)
Figure 31. Other Applications: Anti-viral therapies market – Revenue and Forecast to 2027 (US$ Million)
Figure 32. North America: Anti-Viral Therapies Market, by Key Country – Revenue (2019) (USD Million)
Figure 33. North America Anti-Viral Therapies Market Revenue and Forecast to 2027 (USD Million)
Figure 34. North America: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)
Figure 35. US: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 36. Canada: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 37. Mexico: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 38. Europe: Anti-Viral Therapies Market, by Key Country – Revenue (2019) (USD Million)
Figure 39. Europe Anti-Viral Therapies Market Revenue and Forecast to 2027 (USD Million)
Figure 40. Europe: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)
Figure 41. Germany: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 42. UK: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 43. France: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 44. Spain: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 45. Italy: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 46. Asia Pacific: Anti-Viral Therapies Market, by Key Country – Revenue (2019) (USD Million)
Figure 47. Asia Pacific Anti-Viral Therapies Market Revenue and Forecast to 2027 (USD Million)
Figure 48. China: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 49. Japan: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 50. India: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 51. South Korea: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 52. Australia: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 53. Middle East & Africa: Anti-Viral Therapies Market, by Key Country – Revenue (2019) (USD Million)
Figure 54. Middle East & Africa Anti-Viral Therapies Market Revenue and Forecast to 2027 (USD Million)
Figure 55. Middle East & Africa: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)
Figure 56. Saudi Arabia: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 57. UAE: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 58. South Africa: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 59. South and Central America: Anti-Viral Therapies Market, by Key Country – Revenue (2019) (USD Million)
Figure 60. South and Central America Anti-Viral Therapies Market Revenue and Forecast to 2027 (USD Million)
Figure 61. South and Central America: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)
Figure 62. Brazil: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 63. Argentina: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)
Figure 64. Impact of COVID-19 Pandemic in North American Country Markets
Figure 65. Impact of COVID-19 Pandemic in Europe Country Markets
Figure 66. Impact of COVID-19 Pandemic in Asia-Pacific Country Markets
Figure 67. Impact of COVID-19 Pandemic in Rest of World Country Markets
Figure 68. Growth Strategies Done by the Companies in the Market, (%)
The List of Companies - Anti- Viral Therapies Market
- AbbVie Inc.
- Abbott
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- Johnson & Johnson Services, Inc.
- Merck and Co., Inc.
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Aurobindo Pharma
- AstraZeneca
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For